title: Evaluation of the PyloriTek test for detection of Helicobacter pylori infection in cases with and without eradication therapy.
abstract: OBJECTIVE
  The accuracy of the PyloriTek test (a 1-h rapid urease test) used after eradication therapy of Helicobacter pylori (H. pylori) has not been well clarified. This study was done to evaluate the accuracy of the PyloriTek test results for cases with and without eradication therapy, using culture and histology as gold standard methods, and to establish the suitable timing of the PyloriTek test after eradication treatment.
  
  
  METHODS
  One hundred sixty-three patients undergoing upper endoscopy were randomly selected; 100 patients had not received eradication therapy and 63 had. Three biopsy specimens each were obtained from the gastric antrum and the body for examination by PyloriTek, culture, and histology. The absence of H. pylori was established with negative results from both culture and histology.
  
  
  RESULTS
  In cases without eradication therapy, PyloriTek, correctly identified 66 of 67 H. pylori-positive cases and 30 of 33 H. pylori-negative cases, yielding 98.5% sensitivity and 90.9% specificity. In cases with eradication therapy, PyloriTek gave correct diagnoses in 10 of 17 H. pylori-positive cases and in 45 of 46 H. pylori-negative cases, for 58.8% sensitivity and 97.8% specificity. However, when PyloriTek was used more than 4 months after the end of eradication therapy, both the sensitivity and the specificity increased to 100%.
  
  
  CONCLUSIONS
  Considering time and cost, the use of PyloriTek alone may be satisfactory for detecting H. pylori infection in cases without eradication therapy. When patients are examined more than 4 months after intervention, the use of PyloriTek alone may be sufficient for correctly diagnosing H. pylori infections.
authors.affiliation: First Department of Medicine, Osaka University School of Medicine, Suita, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Murata
authors.forename: S
authors.initials: S
authors.lastname: Kawano
authors.forename: S
authors.initials: S
authors.lastname: Tsuji
authors.forename: M
authors.initials: M
authors.lastname: Tsujii
authors.forename: H
authors.initials: H
authors.lastname: Sawaoka
authors.forename: H
authors.initials: H
authors.lastname: Iijima
authors.forename: N
authors.initials: N
authors.lastname: Kawai
authors.forename: M
authors.initials: M
authors.lastname: Hori
mesh_terms: D000658:Amoxicillin / Q000008:administration & dosage; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D015415:Biomarkers / Q000032:analysis; D017291:Clarithromycin / Q000008:administration & dosage; D004338:Drug Combinations; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology*; D016480:Helicobacter pylori / Q000302:isolation & purification; D006801:Humans; D008297:Male; D008875:Middle Aged; D010406:Penicillins / Q000008:administration & dosage; D054328:Proton Pump Inhibitors; D012680:Sensitivity and Specificity; D013997:Time Factors; D014510:Urease / Q000032:analysis
chemical_list: D000900:Anti-Bacterial Agents; D015415:Biomarkers; D004338:Drug Combinations; D010406:Penicillins; D054328:Proton Pump Inhibitors; D000658:Amoxicillin; D014510:Urease; D017291:Clarithromycin